Cite
HARVARD Citation
von Minckwitz, G. et al. (2016). Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer – The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29). European journal of cancer. pp. 12-21. [Online].